title: [A case of recurrent endometrial carcinoma with pleural effusion maintained long SD by pegylated liposomal doxorubicin(PLD)chemotherapy].
abstract: We experienced a case of long SD through the use of pegylated liposomal doxorubicin(PLD)chemotherapy for recurrent endometrial carcinoma with pleural effusion. The patient was an 82-year-old woman with recurrent endometrial carcinoma. At 76 years of age, she underwent extended abdominal hysterectomy, bilateral salpingo-oophorectomy and pelvic·paraaortic lymphadenectomy for the diagnosis of endometrial carcinoma(serous adenocarcinoma)Stage IIIc. She also received adjuvant chemotherapy with paclitaxel(175mg/m2)and carboplatin(AUC 6), and radiotherapy. Forty-six months after the first treatment, the tumor marker CA125 level was elevated, and recurrent tumors at the vaginal stump and peritoneal dissemination were recognized. Then, second-line chemotherapy with docetaxel(70mg/m2)and carboplatin(AUC5)were administered, and CR was achieved. After 6 months, a second relapse occurred. She felt severe dyspnea from the massive pleural effusion, and underwent PLD(40mg/m2)monotherapy to control the disease progress and to maintain her quality of life. After 5 courses of PLD treatment, the pleural effusion clearly diminished, and the CA125 level decreased. The toxicity was generally mild. This case suggests that PLD may be one of the promising drugs for recurrent endometrial carcinoma.
authors.affiliation: Dept. of Obstetrics and Gynecology, Showa General Hospital.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Miyamoto
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Takechi
mesh_terms: D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D010996:Pleural Effusion / Q000209:etiology*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012008:Recurrence; D014057:Tomography, X-Ray Computed
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin